Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.
Ozenne
Violaine
V
Departments of Hepatology, Hôpital Beaujon, Clichy, AP-HP, France. violaine.ozenne@bjn.aphp.fr
Paradis
Valerie
V
Pernot
Simon
S
Castelnau
Corinne
C
Vullierme
Marie-Pierre
MP
Bouattour
Mohamed
M
Valla
Dominique
D
Farges
Olivier
O
Degos
Françoise
F
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000008:administration & dosage* / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000401:mortality; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011379:Prognosis; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D000077157:Sorafenib; D016019:Survival Analysis; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib